Cytoreductive nephrectomy in metastatic renal cell carcinoma

Current Opinion in Urology

Volumn 18, Issue 5, 2008, Pages 474-480

  Margulis, Vitaly ^a   Matin, Surena F ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytoreductive nephrectomy; Immunotherapy; Renal cell carcinoma; Targeted molecular therapy

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; ERLOTINIB; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CYTOREDUCTIVE SURGERY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; NEPHRON SPARING SURGERY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; KIDNEY TUMOR; TIME;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEPHRECTOMY; PATIENT SELECTION; TIME FACTORS;

EID: 54549120308     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32830a4f21     Document Type: Review

References (50)

1. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-970.
2. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001; 345:1655-1659.
3. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:1071-1076.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
7. Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007; 13:727s-732s.
8. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
9. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results [Abstract 5025]. In: ASCO Annual Meeting Proceedings; 2007.
10. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25:4536-4541.
11. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
12. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon- α2a vs. placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma [Abstract 5024]. In: 2007 ASCO Annual Meeting Proceedings Part 1 2007.
13. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors [Abstract 5024]. In: 2007 ASCO Annual Meeting Proceedings Part 1 2007.
14. Rosenberg JE, Motzer RJ, Michaelson MD, et al. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival [Abstract 5095]. In: 2007 ASCO Annual Meeting Proceedings Part 1 2007.
15. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003; 61:314-319.
16. Choueiri TK, Rini B, Garcia JA, et al. Prognostic factors associated with longterm survival in previously untreated metastatic renal cell carcinoma. Ann Oncol 2007; 18:249-255.
17. Kassouf W, Sanchez-Ortiz R, Tamboli P, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 2007; 178:1896-1900.
18. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma:a stratification tool for prospective clinical trials. J Urol 2005; 174:1759-1763; discussion 1763.
19. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol 2002; 20:2376-2381.
20. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patientswith advanced renalcell carcinoma.JClin Oncol1999; 17:2530-2540.
21. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis asa prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006; 107:1793-1800.
22. Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166:68-72.
23. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296.
24. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98:2566-2575.
25. Choueiri TK,GarciaJA,ElsonP,et al.Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543-550.
26. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [Abstract 5023]. In: 2007 ASCO Annual Meeting Proceedings Part 1 2007.
27. Halbert RJ, Figlin RA, Atkins MB, et al. Treatment of patients with metastatic renal cell cancer: a RAND appropriateness panel. Cancer 2006; 107:2375-2383.
28. Walther MM, Yang JC, Pass HI, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997; 158:1675-1678.
29. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802-811.
30. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11:3714-3721.
31. Walther MM, Alexander RB, Weiss GH, et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 1993; 42:250-257; discussion 257-258.
32. Bennett RT, Lerner SE, Taub HC, et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995; 154:32-34.
33. Rackley R, Novick A, Klein E, et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994; 152:1399-1403.
34. Bex A, Horenblas S, Meinhardt W, et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 2002; 42:570-574; discussion 575-576.
35. Bex A, Kerst M, Mallo H, et al. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 2006; 49:76-81.
36. Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001; 96:173-182.
37. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factormediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002; 105:43-47.
38. Kesmodel SB, Ellis LM, LinE, et al. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer liver metastases [Abstract234].In:ASCO 2007Gastrointestinal CancersSymposium.
39. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2007; 7:73-78.
40. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007; 13:697s-702s.
41. Margulis V, Matin SF, Tannir N, et al. Surgial morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008; 180:94-98.
42. Lam JS, Breda A, Belldegrun AS, Figlin RA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 2006; 24:5565-5575.
43. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003; 169:2076-2083.
44. Canfield SE, Kamat AM, Sanchez-Ortiz RF, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006; 175:864-869.
45. Karakiewicz PI, Trinh QD, Bhojani N, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007; 51:1616-1624.
46. Walther MM, Lyne JC, Libutti SK, Linehan WM. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 1999; 53:496-501.
47. Rabets JC, Kaouk J, Fergany A, et al. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 2004; 64:930-934.
48. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology 2006; 68:528-532.
49. Krambeck AE, Leibovich BC, Lohse CM, et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol 2006; 176:1990-1995; discussion 1995.
50. Hutterer GC, Patard JJ, Colombel M, et al. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer 2007; 110:2428-2433.